Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Xifaxan in Sickle Cell Disease
NCT03719729Phase 2Unknown
- Sponsor
- New York Medical College
- Start
- Aug 2018
- Primary completion
- Feb 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of rifaximin in sickle cell disease (SCD), sponsored by New York Medical College. Primary endpoint: Toxicity profile at 24 months. Status: unknown.
02
Drugs
rifaximin
03
Conditions
sickle cell disease (SCD)
Beyond the preview
Go deeper on NCT03719729.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03719729.